[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-surgery":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,88,117,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054134","appropriateness-of-hemostatic-agent-use-in-cardiovascular-surgery-haemovax-100054134",false,"NCT07699016","Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)","Evaluation of Appropriateness in the Use of Hemostatic Agents in Cardiovascular Surgery: A Mixed-Methods Single-Center Observational Study","HAEMOVAX","Inclusion Criteria:\n\n* Physicians with a surgical role in the Departments of Cardiac Surgery or Vascular Surgery at IRCCS Galeazzi-Sant'Ambrogio, Milan Including attending surgeons, consultant surgeons, and surgical residents\n* Active participation in cardiovascular operative procedures during the study period (or within the preceding 12 months)\n* Employment at the study institution at the time of survey administration Willingness to participate and complete the anonymous structured questionnaire\n\nExclusion Criteria:\n\n* Non-surgical healthcare personnel (e.g., nurses, anesthesiologists, administrative staff, or allied health professionals)\n* Surgeons not involved in operative cardiovascular practice during the study period\n* External collaborators or visiting surgeons without regular clinical activity at the institution\n* Individuals who do not provide informed consent for participation in the anonymous survey\n* Questionnaires with missing or incomplete vignette responses preventing calculation of the KPA-Score",true,"ALL","18 Years",{"count":21,"type":22},15,"ESTIMATED","OBSERVATIONAL","Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making.\n\nHAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.",[26,27,28,29,30],"Hemostasis","Perioperative Bleeding","Cardiovascular Surgery","Cardiac Surgery","Vascular Surgery",[32,33,34,27],"Hemostatic Agents","Surgical Hemostasis","Topical Hemostatic Agents","RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2026-08-15",{"name":45,"class":46},"University of Milan","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100561028","enhanced-vitals-monitoring-after-major-surgery-trial-100561028","NCT06584825","Enhanced Vitals Monitoring After Major Surgery Trial","The Impact of Enhanced Postoperative Vitals Monitoring In-hospital and at Home vs. Standard Care After Inpatient Abdominal and Vascular Surgery: A Pilot Two-centre Randomized Controlled Study","Inclusion Criteria:\n\n1. Undergoing inpatient major abdominal (general surgery, urology, or gynecology) or vascular surgery at St. Paul's Hospital (SPH) and Mount Saint Joseph (MSJ) Hospital\n2. Length of stay of at least 48 hours (planned by the clinical team, or by the Canadian Institute of Health Information Discharge Abstract Database Expected Length of Stay (ELOS) for the surgical case mix group\n3. Self-reported fluency in reading and speaking in English for patient or home caregiver\n4. Living within British Columbia, Canada and in an area that is covered by Bell cellular network (the Cloud DX Inc. device has cellular Long Term Evolution (LTE) using the Bell network).\n\nExclusion Criteria:\n\n1. Patient refusal\n2. Transplant surgery, since these patients have a unique set of considerations and postoperative course.\n3. Inability to communicate with research personnel, perform self-monitoring of vital signs, or complete study surveys due to cognitive, language, visual, or hearing barriers\n4. Lack of capacity to consent to the study (including under the active influence of sedative medication or having received general anesthetic within the past 24 hours)\n5. Unable to use (or does not have a caregiver who can help put on\u002Ftake off) study monitoring device at home\n6. Preoperatively known planned discharge to a nursing home or rehabilitation facility\n7. Patient with known allergic reactions to any part material of the device\n8. Unable to monitor blood pressure accurately noninvasively using arm blood pressure cuffs, such as due to underlying vascular anatomy or non-pulsatile blood flow physiology\n9. Unlikely to be able to return the home monitoring kit (no fixed address, living too far away from site, etc.)","19 Years",{"count":57,"type":22},110,"INTERVENTIONAL",[60],"NA","The aim of this clinical trial is to examine the feasibility of an enhanced vital sign monitoring solution in-hospital and at-home. This study includes adult patients undergoing inpatient major vascular or abdominal surgery. Researchers will compare the enhanced vitals monitoring group to the standard of care group to see if it may change post-operative management and outcomes. The primary question it aims to answer is if enhanced monitoring of surgical patient vitals can increase the number of days at home alive in the first 30 days after surgery. Participants in the intervention group will test two vitals monitoring devices, one in the hospital and one at home. They will also be asked to complete several questionnaires and a follow up phone call.",[63,64,65,66,30,67,68],"Surgery","Post Operative Complications","Quality of Recovery","General Surgery","Urology","Gynecology",[70,71,72,73,74,75,76,77,78],"Days alive and at home","DAH30","Quality of Recovery 15","Pilot Randomized Controlled Trial","vitals","blood pressure","heart rate","oxygen saturation","device","2025-11-17",{"date":81,"type":39},"2025-11-21",{"date":79,"type":39},{"date":84,"type":22},"2027-12-31",{"name":86,"class":46},"University of British Columbia",2,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":58,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100596383","information-on-the-use-of-anti-embolic-stockings-in-patients-undergoing-vein-surgery-100596383","NCT07044739","Information on the Use of Anti-embolic Stockings in Patients Undergoing Vein Surgery","The Effect of Information on the Use of Anti-embolic Stockings on Discharge Readiness and Satisfaction With Nursing Care in Patients Undergoing Vein Surgery","Inclusion Criteria:\n\n• Having had vein surgery\n\nExclusion Criteria:\n\n* Having hearing\u002Fvision\u002Fmental problems\n* Having been diagnosed with a psychological illness (schizophrenia, depression)\n* Having any of the contraindications for the use of anti-embolic stockings in the patient (the patient has peripheral arterial disease or bypass grafts, peripheral neuropathy or other causes of sensory impairment, heart failure, pulmonary or leg edema, poor skin condition due to dermatitis\u002Fdiabetes\u002Fvenous ulcers, allergy or sensitivity to the materials in the stockings, and leg deformities that prevent the stockings from fitting properly)",{"count":96,"type":22},60,[60],"The aim of this study was to investigate the effect of information given to patients undergoing vein surgery regarding the use of anti-embolic stockings on their readiness for discharge and satisfaction with nursing care.",[100,30,101],"Nursing Care","Patient Education",[103,104,105,106],"nursing care","vascular surgery","discharge","postoperative period","NOT_YET_RECRUITING","2025-06-26",{"date":110,"type":39},"2025-07-01",{"date":112,"type":22},"2025-08-15",{"date":114,"type":22},"2026-06-15",{"name":116,"class":46},"Aydin Adnan Menderes University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":47},"100533211","anticoagulation-and-inflammation-monitoring-in-patients-after-heart-and-vascular-interventions-100533211","NCT06222866","Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions","Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions: Prospective Observational Study","PAC-AIM","Inclusion Criteria:\n\n* Age: \\> 17 years\n* Informed written consent\n* Scheduled for cardiac intervention where the use of UFH is expected (elective surgery)\n* Scheduled for vascular intervention when the need for perioperative anticoagulation is expected (elective surgery)\n* Patients receiving ECMO support\n\nExclusion Criteria:\n\n* Patients that are known to be pregnant\n* Known participation in other interventional clinical trial",{"count":126,"type":22},400,"The goal of this prospective observational study is to evaluate the most appropriate anticoagulation monitoring tool for unfractionated heparin (UFH), by comparison of different monitoring modalities in relation to adverse events occurrence (thrombosis\u002Fbleeding).\n\nThe main study questions are:\n\n* What is the most appropriate anticoagulation monitoring tool (ACT, aPTT, viscoelastic tests (ROTEM), and anti-Xa) for UFH\n* What is the incidence of adverse events associated with anticoagulation and inflammation after heart and vascular interventions\n* Is there an association of available anticoagulation thresholds and monitoring tests with bleeding and\u002For thrombosis occurrence\n* Is there an association of inflammation with delirium\n\nSecondary study objectives include:\n\n* Association of anticoagulation levels as measured by ACT, aPTT, viscoelastic tests (ROTEM), and anti-factor-Xa with adverse events\n* Correlation of each anticoagulation monitoring test with the UFH anti-Xa measurement\n* Correlation of each anticoagulation monitoring test with another (ACT, aPTT, ROTEM, anti-F-Xa) and the amount of blood loss post surgery\n* The incidence of UFH-rebound effect and the need for protamine application\n* Association of inflammation and increased \u002F reduced need for anticoagulation titration\n* Correlation of anticoagulation dosing with anticoagulation monitoring tests and adverse events\n* The association of inflammation with adverse events\n* The association and impact of inflammation on measured levels of anticoagulation with available tests\n* Influence of anticoagulation on mortality\n* Incidence of ECMO support\n* Incidence of delirium (hypoactive and hyperactive) and correlation with vital (newly onset postoperative atrial fibrillation amongst others) and laboratory parameters, including, and pre-existing neurological disorders",[129,30,130,131],"Heart Surgery","Delirium","Hyperinflammatory Syndrome",[133,104,134,135,136,130,137],"cardiac surgery","Anticoagulation","Adverse Events","Monitoring","Inflammation","2024-11-25",{"date":140,"type":39},"2024-11-26",{"date":142,"type":39},"2024-06-25",{"date":144,"type":22},"2026-12-01",{"name":146,"class":46},"Medical University Innsbruck",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":23,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":47},"100275283","australian-and-new-zealand-massive-transfusion-registry-100275283","NCT02863250","Australian and New Zealand Massive Transfusion Registry","Improving Outcomes for Patients With Critical Bleeding Requiring Massive Transfusion","ANZ-MTR","Inclusion Criteria:\n\n* aged 18 years or over\n* 5 or more units of red blood cells in any 4 hour period\n\nExclusion Criteria:\n\n* nil",{"count":156,"type":22},50000,"1 Year","Severe and un-stopped blood loss can occur for a number of different reasons including after a serious injury, delivery of a baby and following other medical and surgical emergencies. The investigators understanding of how to best treat people with serious bleeding is still incomplete, with many questions remaining. These include questions regarding how many people have serious bleeding events, what happens to them and the best way to treat them.\n\nThe Massive Transfusion Registry (MTR) is a register of patients who have experienced major blood loss that required a massive transfusion in any clinical setting.\n\nThe MTR uses electronic data extraction and data linkage methodologies. Pre-existing clinical data from hospital data sources, including Laboratory Information Systems (for transfusion history and laboratory results) and Health Information Services databases (for Patient demographics and admission data), are electronically extracted by staff employed at the participating hospitals. The data is then sent to the MTR Research Team, located at Monash University, where it is then linked, analysed and stored.\n\nThe establishment of a Massive Transfusion Registry will be a unique and important resource for clinicians in Australia, New Zealand and internationally, for Blood Services and for the broader community. It will provide valuable observational data regarding the types and frequency of conditions associated with critical bleeding requiring massive transfusion, the use of blood component therapy (i.e. ratios and quantities of different types of red cell to non- red cell components) and patient outcomes.",[160,161,162,163,30,164,165],"Massive Transfusion","Trauma","Cardiothoracic Surgery","Gastrointestinal Bleeding","Obstetric Bleeding","Liver Transplant","2020-08-31",{"date":168,"type":39},"2020-09-02",{"date":170,"type":4},"2011-03",{"date":172,"type":22},"2028-12-31",{"name":174,"class":46},"Monash University"]